Treatment of ovine pituitary follitropin with anhydrous hydrogen fluoride at 0 degrees C for 60 min resulted in the removal of approximately 80% of the sugars without affecting the polypeptide moiety. Fucose, sialic acid and N-acetylgalactosamine were eliminated completely while the loss of hexoses and N-acetylglucosamine amounted to 86% and 56% respectively. The treatment had no effect on the quaternary structure of the hormone. Consistent with the loss of carbohydrate, the elution volume of the hormone on Sephadex G100 was increased and the deglycosylated hormone lost its ability to interact with the lectin concanavalin-A immobilized on Sepharose. Deglycosylation rendered the hormone less acidic as reflected by altered electrophoretic mobility in polyacrylamide gels at pH 8.9 and 4.5. The UV absorption spectrum of the hormone was not affected by deglycosylation but tryptophan fluorescence was slightly decreased. The receptor-binding activity of the hormone as estimated by a specific radioreceptor assay using adult bovine testicular membranes and labeled 125I-FSH was increased by 250% following deglycosylation. In a conformation specific radioimmunoassay, the deglycosylated hormone showed 150% activity as compared to the native hormone. Thus, the full integrity of the carbohydrate moiety in ovine follitropin is not required for effective receptor binding and immunological activity.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0303-7207(82)90026-0 | DOI Listing |
Minerva Obstet Gynecol
January 2025
Unit of Obstetrics and Gynecology, Department of Medical and Surgical Sciences for Mothers, Children and Adults, Policlinic University Hospital, University of Modena and Reggio Emilia, Modena, Italy.
Introduction: Relaxin is a hormone primarily produced by the corpus luteum during pregnancy, and it plays a critical role in various physiological processes related to pregnancy and childbirth.
Evidence Acquisition: Studies have suggested a possible link between relaxin levels and preterm birth. Relaxin's effects on the cervix and pelvic ligaments suggest it could influence the mode of delivery.
Minerva Obstet Gynecol
January 2025
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Introduction: Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine-metabolic syndrome mainly characterized by ovarian dysfunction, which is only one manifestation of a more complex syndrome with a significant systemic impact.
Evidence Acquisition: We review scientific literature on the pathophysiology and diagnosis of PCOS evaluating the most relevant data from original articles, reviews and meta-analyses published until June 2024.
Evidence Synthesis: From a pathophysiological point of view, the concurrence of both metabolic aspects, such as insulin resistance and obesity, and hormonal alterations, such as hyperandrogenemia, might produce the most relevant clinical signs and/symptoms of this syndrome, for instance menstrual irregularities, hair loss, acne and hirsutism.
Endocrine
January 2025
Pediatric Unit, IRCCS AOU of Bologna, Bologna, Italy.
Endocrine
January 2025
Endocrine Unit and Diabetes Centre, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Purpose: Several studies suggest a linkage between PCOS and autoimmunity with a high frequency of chronic autoimmune thyroiditis (AIT) reported in PCOS patients, however, this subject remains controversial. The aim of this study was to investigate the prevalence of AIT in PCOS women and identify parameters that would serve as independent predictors of AIT.
Methods: Two hundred fifty seven (257) PCOS patients according to the NIH criteria and one hundred forty three (143) controls, women with normal menstrual cycles and without clinical or biochemical hyperandrogenism, were recruited for the study.
Rev Endocr Metab Disord
January 2025
Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Biomedical Research Building, 1501 N.W. 10th Avenue, Room 908, Miami, FL, 33136, USA.
Growth hormone (GH)-releasing hormone (GHRH), a hypothalamic peptide initially characterized for its role in GH regulation, has gained increasing attention due to its GH-independent action on peripheral physiology, including that of the cardiovascular system. While its effects on the peripheral vasculature are still under investigation, GHRH and synthetic agonists have exhibited remarkable receptor-mediated cardioprotective properties in preclinical models. GHRH and its analogs enhance myocardial function by improving contractility, reducing oxidative stress, inflammation, and offsetting pathological remodeling.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!